Skip to main content
Realcan Pharmaceutical Group Co.,Ltd. logo

Realcan Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 002589 ISIN · CNE1000013X5 LEI · 300300YI5IV3FBRRSJ48 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,678 across all filing types
Latest filing 2025-01-09 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 002589

About Realcan Pharmaceutical Group Co.,Ltd.

https://www.realcan.cn

Realcan Pharmaceutical Group Co., Ltd. specializes in the distribution of pharmaceutical products, medical devices, and healthcare consumables. The company operates an extensive supply chain network, providing integrated logistics and distribution services primarily to medical institutions and healthcare providers. Its core operations include the procurement, storage, and delivery of a wide range of medical supplies, supported by advanced information management systems and cold-chain logistics capabilities. Realcan also offers value-added services such as hospital supply chain optimization, third-party logistics, and financial solutions tailored to the healthcare industry. By focusing on a direct-to-hospital distribution model, the company aims to enhance the efficiency of medical supply procurement and ensure the timely delivery of critical healthcare products.

Recent filings

Filing Released Lang Actions
关于回购公司股份的进展公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the progress of the company's share repurchase plan. It details the board's approval of the share buyback scheme, the funding sources, the price limits, and the implementation period. It also states that as of the end of December 2024, no shares have been repurchased yet. The document is short (976 characters) and focuses on the status update of the share repurchase activity, not on financial results or detailed financial statements. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback or sale of its own shares.
2025-01-09 Chinese
回购报告书
Transaction in Own Shares Classification · 100% confidence The document is titled as a "回购报告书" which translates to "Share Repurchase Report" or "Buyback Report." It details the company's plan to repurchase its own shares, including the amount, price, method, funding sources, timeline, and related risks. It also includes information about the board's approval, authorization to management, and compliance with regulatory requirements. The document is over 10,000 characters and contains substantive details about the share repurchase program, not just an announcement of a report or a brief notice. This matches the definition of a Transaction in Own Shares (POS) filing, which covers reports of the company buying back its own shares. Therefore, the correct classification is POS with high confidence.
2024-12-11 Chinese
2024年第三次临时股东大会的律师见证法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, attendance, and voting results of the 2024 third extraordinary general meeting (临时股东大会) of shareholders of 瑞康医药集团股份有限公司. It details the legal compliance of the meeting's call, attendance, agenda, and voting process, and confirms the validity of the resolutions passed, specifically the reappointment of the accounting firm. The document does not contain financial statements or detailed financial performance data, nor is it a report or announcement of financial results. It is a legal opinion related to the shareholder meeting and its resolutions, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, but it contains detailed voting results and legal opinion, not just a brief announcement or notice, so it is not a Report Publication Announcement (RPA). Therefore, the best classification is DVA.
2024-12-09 Chinese
2024年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an announcement of the resolutions passed at the 2024 third extraordinary general meeting of shareholders of Ruikang Pharmaceutical Group Co., Ltd. It includes details about the meeting notice, attendance, voting results, and legal opinion on the meeting's validity. The document does not contain financial statements or detailed financial analysis but reports the official voting results of the shareholder meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1587 characters), and it is not a report itself but an announcement of meeting outcomes.
2024-12-09 Chinese
关于2022年员工持股计划股票出售完毕的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of the sale of shares held under the company's 2022 employee stock ownership plan. It details the plan's approval, stock transfer, lock-up period, early termination decision, and final sale of shares. The document is relatively short (1651 characters) and serves as a formal disclosure of the stock sale completion and related compliance with regulatory requirements. It does not contain financial statements, detailed financial analysis, or management discussion. It is not a full report but an official announcement about the employee stock plan's status and stock sale completion. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2024-12-05 Chinese
2024年前三季度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an "权益分派实施公告" which translates to "Implementation Announcement of Equity Distribution" for the first three quarters of 2024. It details the dividend distribution plan approved at a shareholders' meeting, including dividend amounts, record dates, and payment methods. The document is relatively short (2053 characters) and primarily serves as an announcement of the dividend distribution plan and its implementation, rather than a full financial report or detailed earnings release. It does not contain comprehensive financial statements or management discussion but focuses on the dividend payout details. According to the filing definitions and rules, announcements about dividend amounts and payment details fall under the category "Notice of Dividend Amount (DIV)". Therefore, this document should be classified as a Notice of Dividend Amount (DIV).
2024-11-22 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.